26Aug 2023
Targeting CK2-mediated phosphorylation of p53R2 sensitizes BRCA-proficient cancer cells to PARP inhibitors

Targeting CK2-mediated phosphorylation of p53R2 sensitizes BRCA-proficient cancer cells to PARP inhibitors

Discover an innovative approach to enhance PARP inhibitor effectiveness in BRCA1/2 wild-type cancers. Depleting p53R2, reducing HR factor CtIP, and inhibiting CK2 phosphorylation synergize with PARP inhibition, rendering these cancers more susceptible. This strategy offers a promising synthetic lethal combination for improved therapeutic outcomes.

  • #oncology

Like

Save

Share